Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celBusiness Wire • 04/28/26
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their ShareholdersGlobeNewsWire • 03/19/26
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover DealThe Motley Fool • 03/16/26
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLXBusiness Wire • 03/13/26
Arcellx President Sells $10M Worth of Shares After Acquisition AnnouncementThe Motley Fool • 03/02/26
Arcellx President Sells $10 Million Worth of Shares After Acquisition AnnouncementThe Motley Fool • 03/02/26
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX)PRNewsWire • 02/23/26
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public ShareholdersPRNewsWire • 02/23/26
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its ShareholdersBusiness Wire • 02/23/26
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-celBusiness Wire • 02/23/26
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celBusiness Wire • 02/23/26
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia CompetitionThe Motley Fool • 02/17/26
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain BinderBusiness Wire • 02/04/26